Neoadjuvant therapy in the treatment of breast cancer

Surgical Oncology Clinics of North America

Volumn 23, Issue 3, 2014, Pages 505-523

  Teshome, Mediget ^a   Hunt, Kelly K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Pathologic complete response; Preoperative chemotherapy

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; LETROZOLE; METHOTREXATE; PACLITAXEL; PERTUZUMAB; PLACEBO; TAMOXIFEN; TRASTUZUMAB; TAXOID;

ADVANCED CANCER; BREAST CANCER; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; LYMPH NODE DISSECTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PARTIAL MASTECTOMY; PERSONALIZED MEDICINE; REVIEW; SENTINEL LYMPH NODE DISSECTION; SKIN TOXICITY; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME; BREAST NEOPLASMS; FEMALE; GENETICS; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; PROTO ONCOGENE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; PROGNOSIS; TAXOIDS;

EID: 84901651346     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2014.03.006     Document Type: Review

References (64)

1. Mamounas E.P., Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 2001, 28:389-399.
2. Fisher B., Gunduz N., Saffer E.A. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983, 43:1488-1492.
3. Ragaz J., Baird R., Rebbeck P., et al. Neoadjuvant (preoperative) chemotherapy for breast cancer. Cancer 1985, 56:719-724.
4. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. JClin Oncol 1998, 16:2672-2685.
5. Rastogi P., Anderson S.J., Bear H.D., et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel project protocols B-18 and B-27. JClin Oncol 2008, 26:778-785.
6. van der Hage J.A., van de Velde C.J., Julien J.P., et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. JClin Oncol 2001, 19:4224-4237.
7. Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. JNatl Cancer Inst 2005, 97:188-194.
8. Mieog J.S., van der Hage J.A., van de Velde C.J. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 2007, 94:1189-1200.
9. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. JClin Oncol 1999, 17:460-469.
10. Mazouni C., Peintinger F., Wan-Kau S., et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. JClin Oncol 2007, 25:2650-2655.
11. Kaufmann M., von Minckwitz G., Mamounas E.P., et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012, 19:1508-1516.
12. Ju N.R., Jeffe D.B., Keune J., et al. Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2013, 137:195-201.
13. Gonzalez-Angulo A.M., McGuire S.E., Buchholz T.A., et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. JClin Oncol 2005, 23:7098-7104.
14. Prowell T.M., Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. NEngl J Med 2012, 366:2438-2441.
15. Symmans W.F., Peintinger F., Hatzis C., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. JClin Oncol 2007, 25:4414-4422.
16. Jeruss J.S., Mittendorf E.A., Tucker S.L., et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. JClin Oncol 2008, 26:246-252.
17. Mittendorf E.A., Jeruss J.S., Tucker S.L., et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. JClin Oncol 2011, 29:1956-1962.
18. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
19. Houssami N., Macaskill P., von Minckwitz G., et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 2012, 48:3342-3354.
20. Guarneri V., Broglio K., Kau S.W., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. JClin Oncol 2006, 24:1037-1044.
21. von Minckwitz G., Untch M., Blohmer J.U., et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. JClin Oncol 2012, 30:1796-1804.
22. Chen S., Chen C.M., Yu K.D., et al. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. Ann Surg Oncol 2012, 19:3002-3011.
23. Mittendorf E.A., Wu Y., Scaltriti M., et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009, 15:7381-7388.
24. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. JClin Oncol 2005, 23:3676-3685.
25. Buzdar A.U., Valero V., Ibrahim N.K., et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007, 13:228-233.
26. Untch M., Rezai M., Loibl S., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. JClin Oncol 2010, 28:2024-2031.
27. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
28. Untch M., Fasching P.A., Konecny G.E., et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. JClin Oncol 2011, 29:3351-3357.
29. Semiglazov V., Eiermann W., Zambetti M., et al. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol 2011, 37:856-863.
30. Untch M., Loibl S., Bischoff J., et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012, 13:135-144.
31. Baselga J., Bradbury I., Eidtmann H., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640.
32. Gianni L., Pienkowski T., Im Y.H., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32.
33. Guarneri V., Frassoldati A., Bottini A., et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. JClin Oncol 2012, 30:1989-1995.
34. Rimawi M.F., Mayer I.A., Forero A., et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. JClin Oncol 2013, 31:1726-1731.
35. Schneeweiss A., Chia S., Hickish T., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013, 24:2278-2284.
36. Liedtke C., Mazouni C., Hess K.R., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. JClin Oncol 2008, 26:1275-1281.
37. Carey L.A., Dees E.C., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334.
38. Nahleh Z. Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook. Med Oncol 2010, 27:531-539.
39. Chang H.R., Glaspy J., Allison M.A., et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 2010, 116:4227-4237.
40. Dowsett M., Smith I.E., Ebbs S.R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. JNatl Cancer Inst 2007, 99:167-170.
41. Eiermann W., Paepke S., Appfelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001, 12:1527-1532.
42. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. JClin Oncol 2005, 23:5108-5116.
43. Cataliotti L., Buzdar A.U., Noguchi S., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006, 106:2095-2103.
44. Ellis M.J., Suman V.J., Hoog J., et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. JClin Oncol 2011, 29:2342-2349.
45. Semiglazov V.F., Semiglazov V.V., Dashyan G.A., et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007, 110:244-254.
46. von Minckwitz G., Kummel S., Vogel P., et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. JNatl Cancer Inst 2008, 100:542-551.
47. von Minckwitz G., Kummel S., Vogel P., et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. JNatl Cancer Inst 2008, 100:552-562.
48. Oh J.L., Nguyen G., Whitman G.J., et al. Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer 2007, 110:2420-2427.
49. Peintinger F., Kuerer H.M., Anderson K., et al. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol 2006, 13:1443-1449.
50. Hylton N.M., Blume J.D., Bernreuter W.K., et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY TRIAL. Radiology 2012, 263:663-672.
51. De Los Santos J.F., Cantor A., Amos K.D., et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer 2013, 119:1776-1783.
52. Newman L.A., Buzdar A.U., Singletary S.E., et al. Aprospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol 2002, 9:228-234.
53. Weksberg D.C., Allen P.K., Hoffman K.E., et al. Outcomes and predictive factors for salvage therapy after local-regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol 2013, 20:3430-3437.
54. Chen A.M., Meric-Bernstam F., Hunt K.K., et al. Breast conservation after neoadjuvant chemotherapy. Cancer 2005, 103:689-695.
55. Akay C.L., Meric-Bernstam F., Hunt K.K., et al. Evaluation of the MD Anderson prognostic index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 2012, 19:901-907.
56. Meyers M.O., Klauber-Demore N., Ollila D.W., et al. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol 2011, 18:2851-2857.
57. Hunt K.K., Yi M., Mittendorf E.A., et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 2009, 250:558-566.
58. Tan V.K., Goh B.K., Fook-Chong S., et al. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer-a systematic review and meta-analysis. JSurg Oncol 2011, 104:97-103.
59. Alvarado R., Yi M., Le-Petross H., et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol 2012, 19:3177-3184.
60. Boughey J.C., Suman V.J., Mittendorf E.A., et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial. JAMA 2013, 310:1455-1461.
61. Hu Y.Y., Weeks C.M., In H., et al. Impact of neoadjuvant chemotherapy on breast reconstruction. Cancer 2011, 117:2833-2841.
62. Gouy S., Rouzier R., Missana M.C., et al. Immediate reconstruction after neoadjuvant chemotherapy: effect on adjuvant treatment starting and survival. Ann Surg Oncol 2005, 12:161-166.
63. Decker M.R., Greenblatt D.Y., Havlena J., et al. Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Surgery 2012, 152:382-388.
64. McGuire S.E., Gonzalez-Angulo A.M., Huang E.H., et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007, 68:1004-1009.